[HTML][HTML] Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Z Ren, A Zhang, Z Sun, Y Liang, J Ye… - The Journal of …, 2022 - pubmed.ncbi.nlm.nih.gov
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti-PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti-PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
[引用][C] Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Z Ren, A Zhang, Z Sun, Y Liang, J Ye, J Qiao… - Journal of Clinical …, 2022 - cir.nii.ac.jp
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with
reduced toxicity | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
reduced toxicity | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
Selective delivery of low-affinity IL-2 to [PD-1. sup.+] T cells rejuvenates antitumor immunity with reduced toxicity.
Z Ren, A Zhang, Z Sun, Y Liang, J Ye, J Qiao… - Journal of Clinical …, 2022 - go.gale.com
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti-PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti-PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Z Ren, A Zhang, Z Sun, Y Liang, J Ye… - Journal of Clinical …, 2022 - search.proquest.com
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti-PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti-PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Z Ren, A Zhang, Z Sun, Y Liang… - Journal of …, 2022 - utsouthwestern.elsevierpure.com
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.
Z Ren, A Zhang, Z Sun, Y Liang, J Ye… - The Journal of …, 2022 - europepmc.org
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
[HTML][HTML] Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Z Ren, A Zhang, Z Sun, Y Liang, J Ye… - The Journal of …, 2022 - ncbi.nlm.nih.gov
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity.
Z Ren, A Zhang, Z Sun, Y Liang, J Ye… - The Journal of …, 2022 - europepmc.org
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …
anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers …